Effect of coenzyme Q10 in fibromyalgia patients: study of symptoms and gene expression
| ISRCTN | ISRCTN21164124 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN21164124 |
| Secondary identifying numbers | N/A |
- Submission date
- 07/08/2012
- Registration date
- 12/09/2012
- Last edited
- 28/05/2014
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Plain English summary of protocol
Background and study aims
Fibromyalgia (FM) is a chronic, long-term condition that causes pain all over the body. It affects approximately 2% of the general population. People with the condition may suffer from a generalised increased sensitivity to pain (hyperalgesia) and a wide range of other symptoms such as allodynia (pain caused by stimuli that would not normally be painful), fatigue (extreme tiredness), joint stiffness and migraines. The treatments currently available only work to some extent. It is not known what causes FM but levels of Coenzyme Q10 (CoQ10), a fat-soluble nutrient that we produce naturally in our bodies, have been found to be low in FM sufferers. The purposes of this study are to assess the effect of CoQ10 on the symptoms of FM patients and to look at the conditions inflammatory gene expression profile.
Who can participate?
Patients between 18 and 65 who have been diagnosed with FM
What does the study involve?
Patients are randomly placed into one of two groups. One group will be given CoQ10, and the other group a placebo. We hope to find a novel therapeutic approach for FM
What are the possible benefits and risks of participating?
Preliminary data have shown some improvements in the clinical symptoms for FM sufferers. There are no known adverse effects from the oral CoQ10 treatment.
Where is the study run from?
University of Sevilla, Spain
When is study starting and how long is it expected to run for?
September 2012 to June 2013
Who is funding the study?
Andalusian Federation of Fibromyalgia and Chronic Fatigue Syndrome, Spain
Who is the main contact?
Professor Pedro Bullón
pbullon@us.es
Contact information
Scientific
University of Sevilla
Department of Periodontology
Dental School
C/Avicena s/n
Sevilla
41009
Spain
| pbullon@us.es |
Study information
| Study design | Randomised placebo controlled double blinded trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | A pilot randomized placebo-controlled trial of coenzyme Q10 in fibromyalgia patients |
| Study objectives | Coenzyme Q10 (CoQ10) is an essential electron carrier in the mitochondrial respiratory chain and a strong antioxidant. Low CoQ10 levels has been detected in patients with Fibromyalgia (FM). The purpose of the present work was to assess the effect of CoQ10 on symptoms of patients with FM and evaluate the inflammatory gene expression profile in blood mononuclear cells from FM patients. |
| Ethics approval(s) | University of Sevilla Ethics Committee, 7 July 2012 |
| Health condition(s) or problem(s) studied | Fibromyalgia |
| Intervention | The participants will be randomly allocated to the following two arms (randomisation ratio 1:1): Intervention group: 300 mg ubiquinone capsule (oral) (Pharmanord, Vejle, Denmark) three times daily for 3 months Control group: Placebo (lactose powder) in similar capsules twice daily for 3 months Total duration of follow-up: 90 days |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | Coenzyme Q10 |
| Primary outcome measure | 1. Coenzyme Q10 levels by High-performance liquid chromatography (HPLC) 2. Oxidative stress by spectrophotometic methods and flow cytometer 3. Inflamation parameters by Enzyme-linked immunosorbent (ELISA) assays 4. Clinical symptoms using diagnostic criteria ACR 1990, Fibromyalgia Impact Questionnaire (FIQ), Visual Analogue Scale (VAS) of pain, Beck Depression Inventory (BDI) (depression), and Pittsburgh test to determinate the quality of dream. |
| Secondary outcome measures | Gene expression by Real time polymerase chain reaction (PCR) |
| Overall study start date | 15/09/2012 |
| Completion date | 01/06/2013 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 20 |
| Key inclusion criteria | 1. Male and female patients between 18 and 65 years old 2. Has FM according to official diagnostic criteria for FM established in 1990 by the American College of Rheumatology (ACR) 3. Duration of the illness of ten years or less |
| Key exclusion criteria | 1. History of renal failure (creatinine equal to or superior than 1.8 mL/dL), coronary disease in the last six months, angina, congestive heart disease, diabetes mellitus type one and two 2. Any life-threatening chronic disease (i.e., cancer disease, inflammatory bowel disease and active immune disorders) 3. Rheumatic disease (i.e., inflammatory arthritis, polymyositis, polymyalgia rheumatica) 4. Osteomalacia and osteoporosis 5. Metabolic and endocrine disease (i.e., hypothyroidism and hyperthyroidism, hyperparathyroidism, adrenal insufficiency, metabolic myopathy) 6. Infectious diseases (i.e., Epstein-Barr virus disease, brucellosis) 7. Rheumatic disease of soft tissue and myofascial pain syndrome 8. Parkinsons disease 9. Women to become pregnant or nursing 10. Patients who are enrolled in other clinical trial or patients who participated in other clinical trial in the last 30 days 11. Any psychological or psychiatric disease to compromise the understanding of the instructions giving by the investigator 12. Any subject to be unable to follow a good complementation of the treatment 13. Any patient who denies to give the informed consent to participate in this trial |
| Date of first enrolment | 15/09/2012 |
| Date of final enrolment | 01/06/2013 |
Locations
Countries of recruitment
- Spain
Study participating centre
41009
Spain
Sponsor information
Charity
[Federación Andaluza de Fibromialgia y Fatiga crónica]
C/ Virog local 10 y 11
Jerez de la Frontera - Cádiz
11406
Spain
| Website | http://www.confederacionfmfc.org/ |
|---|
Funders
Funder type
Charity
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 20/10/2013 | Yes | No |
